HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Foghorn Therapeutics (NASDAQ:FHTX) and maintained a $20 price target.
June 08, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Foghorn Therapeutics and maintained a $20 price target.
The reiteration of a Buy rating and maintenance of a $20 price target by HC Wainwright & Co. analyst Andrew Fein indicates a positive outlook for Foghorn Therapeutics. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100